PL4293025T3 - Kompozycja 4-aminochinazoliny - Google Patents

Kompozycja 4-aminochinazoliny

Info

Publication number
PL4293025T3
PL4293025T3 PL22752855.1T PL22752855T PL4293025T3 PL 4293025 T3 PL4293025 T3 PL 4293025T3 PL 22752855 T PL22752855 T PL 22752855T PL 4293025 T3 PL4293025 T3 PL 4293025T3
Authority
PL
Poland
Prior art keywords
aminoquinazoline
composition
aminoquinazoline composition
Prior art date
Application number
PL22752855.1T
Other languages
English (en)
Polish (pl)
Inventor
Kenichi Kawaguchi
Kazuyuki Kuramoto
Tomoyoshi IMAIZUMI
Takahiro Morikawa
Mitsuaki Okumura
Sunao Imada
Eiji Kawaminami
Ryo Sato
Yohei Seki
Hisao Hamaguchi
Hiroki Ishioka
Hiroki Fukudome
Ikumi Kuriwaki
Takeyuki Nagashima
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL4293025T3 publication Critical patent/PL4293025T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL22752855.1T 2021-02-15 2022-02-14 Kompozycja 4-aminochinazoliny PL4293025T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021021684 2021-02-15
PCT/JP2022/005583 WO2022173033A1 (ja) 2021-02-15 2022-02-14 4-アミノキナゾリン化合物

Publications (1)

Publication Number Publication Date
PL4293025T3 true PL4293025T3 (pl) 2026-02-16

Family

ID=82838845

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22752855.1T PL4293025T3 (pl) 2021-02-15 2022-02-14 Kompozycja 4-aminochinazoliny

Country Status (12)

Country Link
US (1) US20240150366A1 (cg-RX-API-DMAC7.html)
EP (1) EP4293025B1 (cg-RX-API-DMAC7.html)
JP (1) JP7725511B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230145360A (cg-RX-API-DMAC7.html)
CN (1) CN116867788B (cg-RX-API-DMAC7.html)
AU (1) AU2022219651A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211110A1 (cg-RX-API-DMAC7.html)
ES (1) ES3054794T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023009520A (cg-RX-API-DMAC7.html)
PL (1) PL4293025T3 (cg-RX-API-DMAC7.html)
SA (1) SA523450286B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022173033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7629580B1 (ja) 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
CA3255513A1 (en) * 2022-03-11 2025-03-04 Astellas Pharma Inc. HETEROCYCLIC COMPOUND TO INDUCE DETERIORATION OF G12D MUTATION KRAS PROTEIN
EP4568674A1 (en) * 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
WO2024188281A1 (zh) * 2023-03-13 2024-09-19 南京明德新药研发有限公司 含喹唑啉结构的化合物及其应用
WO2025052649A1 (ja) * 2023-09-08 2025-03-13 アステラス製薬株式会社 単一の軸不斉化合物の選択的製造法
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
WO2016049565A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Compositions and methods for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JOP20190186A1 (ar) * 2017-02-02 2019-08-01 Astellas Pharma Inc مركب كينازولين
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Also Published As

Publication number Publication date
EP4293025B1 (en) 2025-10-29
WO2022173033A1 (ja) 2022-08-18
JPWO2022173033A1 (cg-RX-API-DMAC7.html) 2022-08-18
SA523450286B1 (ar) 2024-06-12
EP4293025A1 (en) 2023-12-20
CA3211110A1 (en) 2022-08-18
JP7725511B2 (ja) 2025-08-19
KR20230145360A (ko) 2023-10-17
MX2023009520A (es) 2023-08-24
EP4293025A4 (en) 2025-02-26
US20240150366A1 (en) 2024-05-09
ES3054794T3 (en) 2026-02-06
EP4293025C0 (en) 2025-10-29
CN116867788B (zh) 2026-05-26
CN116867788A (zh) 2023-10-10
AU2022219651A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
EP4227390A4 (en) COMPOSITION CONTAINING A REFRIGERANT FLUID
EP4148096A4 (en) COMPOSITION
EP4094582A4 (en) COMPOSITION
EP4328279A4 (en) COMPOSITION
EP4115893A4 (en) Anti-tumor composition
EP4279545A4 (en) COMPOSITION
EP4043002A4 (en) Dental composition
PL3896109T3 (pl) Kompozycja utwardzalna
EP3871694A4 (en) COMPOSITION
EP4313320A4 (en) ANTIPERSPIRANT COMPOSITION
EP4330366C0 (en) COMPOSITION
EP3981256A4 (en) COMPOSITION
EP3954721A4 (en) Composition
EP3941942A4 (en) COMPOSITION
EP3914303C0 (en) VIRUCIDAL COMPOSITION
EP3741814C0 (en) COMPOSITION
EP4372077A4 (en) AUTOPHAGY-ACTIVATING COMPOSITION
EP4337752C0 (en) COMPOSITION
EP4392085A4 (en) Injectable composition
EP4256012C0 (en) COMPOSITION
EP4291042C0 (en) COMPOSITION DERIVED FROM OATS
EP4656252A4 (en) COMPOSITION
EP4454715A4 (en) COMPOSITION
EP4553110A4 (en) COMPOSITION
EP4403170A4 (en) COMPOSITION CONTAINING CARYOPHYLLENE